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that reﬂ ects clinically severe disease–eg, the need for 
unscheduled medical attention and hospital admission 
for physician-diagnosed wheeze. The use by Stokholm 
and colleagues11 of “troublesome lung symptoms” as 
the primary outcome means that the beneﬁ cial eﬀ ect 
of azithromycin could possibly be mediated via the 
bronchitis and not the wheeze component of preschool 
wheeze. Indeed, postviral bronchitis is probably assoc-
iated with abnormal bacterial colonisation of the lower 
airway and thus might be amenable to antibacterial 
treatment.13 If, however, azithromycin reduces wheeze 
severity, then this study becomes mechanistically very 
important. On one hand, improved resolution of wheeze 
could happen via a direct antimicrobial eﬀ ect if bacteria 
increase proinﬂ ammatory cytokine release from viral-
infected airway cells. On the other hand, and perhaps 
more likely, an eﬀ ect on wheeze could be mediated by 
either the anti-inﬂ ammatory activity of azithromycin 
or its ability to directly inhibit replication of human 
rhinovirus in airway epithelial cells.14
Overall, the study by Stokholm and colleagues11 
cannot, without further evidence from trials using 
markers of clinically severe wheeze as the primary 
outcome, be used to justify the widespread or even 
selective use of azithromycin for troublesome lower 
respiratory tract symptoms with wheeze in this age 
group. By signposting new mechanisms underlying 
the pattern of lower respiratory symptoms—currently 
labelled as preschool wheeze—this study serves as an 
important reminder that robust studies of generic drugs 
for new indications have the capacity to substantially 
advance understanding of the mechanisms of common 
respiratory disorders.
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Beneﬁ cial eﬀ ect of NMES in COPD wanes after programme 
completion
Chronic obstructive pulmonary disease (COPD) is 
predicted to become the third leading cause of death by 
2030.1 COPD is now considered a systemic disease, with 
patients often presenting with symptoms beyond the 
respiratory system and coexisting co morbidities.2 The 
musculoskeletal system is aﬀ ected early in the disease 
process with sarcopenia and exercise intolerance being 
more evident in moderate to severe COPD.2,3 More 
importantly exercise intolerance carries important 
prognostic information.4  
In a disease that is both incurable and progressive, 
important goals of eﬀ ective management include 
symptom control, avoidance of exacerbations and 
complications, and improvement of exercise tolerance.2 
Pulmonary rehabilitation is considered one of the 
cornerstones of COPD management because it not only 
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improves exercise capacity, thus enabling patients to 
maintain higher levels of physical activity and preserve 
their independence, but also improves quality of life 
and symptom control.2,5 Pulmonary rehabilitation is also 
recommended for avoidance of exacerbations.2
Nevertheless, a major proportion of patients with COPD 
are unable to attend a structured pulmonary rehabilitation 
programme. Reasons are of course multi factorial; 
however, patients with COPD, especially those with 
advanced disease, could often be housebound, too weak 
for conventional rehabilitation programmes, or simply 
unwilling to participate in a structured rehabilitation 
programme. These patients are therefore deprived of the 
aforementioned beneﬁ ts of physical exercise.
Neuromuscular electrical stimulation (NMES) is an 
alternative exercise method that has been eﬀ ectively 
used even in critically ill patients as it does not require 
patient cooperation.6 Moreover, NMES has minimal 
ventilatory and cardiovascular requirements.7 Usually 
the quadriceps—a muscle that is pivotal for walking—is 
stimulated. More importantly though, NMES has been 
shown to induce a systemic eﬀ ect.7 Unsurprisingly, 
several studies have therefore evaluated the eﬀ ect of 
NMES in patients with COPD.8 
In The Lancet Respiratory Medicine, Matthew Maddocks 
and colleagues9 in a double-blind, placebo-controlled 
study evaluated the eﬀ ect of 6 weeks home-based 
NMES on exercise capacity and muscle function. First, 
the study design is very robust in that it includes both 
sham NMES and blinding of the patients and the 
outcome assessors. The authors very appropriately 
focused on a subgroup of patients with severe COPD 
and incapacitating breathlessness. They have also 
included a plethora of outcome measures with exercise 
capacity as their primary endpoint in an attempt to 
achieve an integrated evaluation of the intervention. 
Most studies so far that assessed the role of NMES 
in patients with COPD had several limitations with 
the methods (such as lack of blinding) and did not 
incorporate a wide range of outcome measures.8 
However, there are issues of the methods used 
that merit attention and could have lead to 
underestimating the results of the intervention. The 
authors reported that 6 weeks of NMES induced a 
moderate—but clinically signiﬁ cant—improvement in 
exercise capacity (change in 6-min walk test distance in 
the active NMES group [mean 29·9 (95% CI 8·9–51·0)] 
compared with in the placebo group [–5·7 (–19·9 to 
8·4)]; mean diﬀ erence at 6 weeks 35·7 m [95% CI 
10·5–60·9]; p=0·005) as well as in quadriceps strength 
and cross-sectional area. However, looking at the data, 
the quadriceps mass of some patients in the sham 
NEMS group also seemed to increase. Possibly in an 
attempt to avoid unmasking, the authors chose to use 
relatively high sham current amplitudes (mean value 
15·5 mA by the end of the programme), which are 
similar to amplitudes used in the active NMES group in 
other studies.8,10 The so-called intensity of the stimulus 
is determined by several characteristics of the current, 
but because NMES also has a systemic eﬀ ect, some 
of the changes noted in the sham group might be 
attributable to NMES after all, thus leading to smaller 
between group diﬀ erences.
Interestingly, the results of the programme seemed 
to wane 6 weeks after its completion (7·3 m [95% CI 
–32·5 to 47·0]; p=0·50. This is the ﬁ rst study to follow 
patients after the completion of an NMES programme. 
Disappointing as they may be, the results are not 
surprising; but they do raise several questions. Should 
NMES be used as a bridge to conventional pulmonary 
rehabilitation? Should it be coupled with lifestyle and 
behavioural changes in order for patients to engage 
in daily physical activities that would help them to 
maintain the beneﬁ cial eﬀ ects of the programme? 
Future studies should also focus on optimisation of 
some of the characteristics of NMES as well as the 
duration of the programme, because 6 weeks is probably 
the minimum time required for beneﬁ cial results.
In summary, the study by Maddocks and colleagues is 
a well designed and executed study assessing a clinically 
relevant issue. NMES seems to render beneﬁ cial, albeit 
short-lived, results in patients with severe COPD unable 
to complete a conventional rehabilitation programme. 
Further studies are necessary to assess the optimum 
characteristics of NMES, the duration of the programme, 
and to better deﬁ ne the role of NMES in the arsenal of 
pulmonary rehabilitation. 
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Big problem, small incidence, and large registry datasets 
In this issue John Fiadjoe and colleagues1 present 
the ﬁ rst 30 months of data from the Pediatric 
Diﬃ  cult Intubation (PeDI) registry, a collaboration of 
13 children’s hospitals in the USA that aims to improve 
understanding of the causes and complications of 
diﬃ  cult tracheal intubation in children. The researchers 
are to be applauded for their fantastic eﬀ ort to gain 
more knowledge on a very complex, diverse group 
of patients at especially high risk for perioperative 
complications. Data collection was well planned and 
best eﬀ orts were undertaken to standardise data 
collection. However, the data were purely observational, 
and airway management was not randomised; as such, 
the data should not be overinterpreted. 
Generally, registry data have many known and unknown 
confounders that cannot be corrected for even with 
complex statistical methods.2 These associations cannot be 
interpreted as causations. Additionally, in the PeDI registry, 
the denominator for diﬃ  cult intubations was unknown 
because only children with (suspected) diﬃ  cult airways 
were included, but no data were collected on the overall 
population of intubated children. Furthermore, in most 
institutions, more than half of paediatric patients receive 
supraglottic airway devices rather than endotracheal 
tubes. This probably led to a signiﬁ cant number of patients 
with known or unknown diﬃ  cult intubations who were 
not included in the registry. The diﬃ  cult intubation rate 
per 1000 intubations is therefore probably substantially 
higher than the incidence reported in this study because 
the rate is given per anaesthetic and not per intubation. 
Unfortunately, children with diﬃ  cult airways managed 
by non-anaesthesiologists in the emergency department 
or on the intensive care unit were not included in the PeDI 
registry. This cohort of patients would be of particular 
interest because managing diﬃ  cult airways outside 
theatres has been linked to worse outcomes.
Underreporting is a well-known problem of large 
registries.  It is therefore likely that the rate of mild and 
severe complications was higher than that reported. It 
is diﬃ  cult to generalise the reported complication rates 
to smaller and less specialised centres. Centres willing 
to participate in such a registry are more likely to have 
experts in paediatric airway management; however, 
such centres are also more likely to care for children 
with more co-morbidities presenting with more diﬃ  cult 
airways.3 Furthermore, complication rates will not only 
depend on patients, skills, and anaesthetic management 
but also on procedures (eg, the reported complication 
rate varied between 14 and 29% in the four highest 
contributing centres).
So, what can we take from the study? Multiple 
attempts at direct laryngoscopy in children with a 
diﬃ  cult airway were associated with a high failure rate 
and an increased incidence of complications. These 
ﬁ ndings conﬁ rm what has been shown in clinical 
practice; however, it is surprising that 20% of all 5th 
attempts were still made by trainee anaesthesiologists. 
Of course, trainees need the opportunity to learn, but 
at what cost? Maybe the three strikes and you are out 
policy from baseball should be introduced, which is 
already common in many institutions for the airway 
management of children, and possibly a two strike 
policy for children with suspected or known diﬃ  cult 
airway. Data were not supplied, but it is possible 
that direct laryngoscopy was performed ﬁ ve times in 
succession without changing the intubation technique. 
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